Histological markers of risk and the role of high-grade prostatic intraepithelial neoplasia

Urology

Volumn 57, Issue 4, 2001, Pages 115-120

  Sakr, Wael A ^a   Partin, Alan W ^a  

^a HARPER UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TELOMERASE;

CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RISK; CARCINOGENESIS; CONFERENCE PAPER; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; MOLECULAR GENETICS; ONCOGENE C MYB; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA;

ADENOCARCINOMA; AGE FACTORS; APOPTOSIS; BIOLOGICAL MARKERS; BIOPSY; CELL DIVISION; HUMANS; MALE; NEOPLASM PROTEINS; PREVALENCE; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; TELOMERASE;

EID: 0034975530     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(00)00953-5     Document Type: Article

References (52)

1. Frequency of prostatic intraepithelial neoplasia and invasive carcinoma in young males
2. Atypical adenomatous hyperplasia of the prostate: A critical review
3. Atypical adenomatous hyperplasia of the prostate: A premalignant lesion?
4. Nucleolar and AgNOR analyses of prostatic intraepithelial neoplasia (PIN), atypical adenomatous hyperplasia (AAH), and prostatic carcinoma
5. Proliferating cell nuclear antigen/cyclin in incidental carcinoma of the prostate
6. Atypical adenomatous hyperplasia of the prostate: Immunophentype, genotype and DNA ploidy analysis
7. Prostatic intra-epithelial neoplasia and early invasion in prostate cancer
8. Introductory remarks and workshop summary
9. Construction of a representative cDNA library from prostatic intraepithelial neoplasia
10. The relationship between prostatic intraepithelial neoplasia and prostate cancer: Critical issues
11. Numerical chromosomal changes in high-grade prostatic intraepithelial neoplasia (PIN) and concomitant invasive carcinoma
12. Evaluation of prostatic intraepithelial neoplasia after treatment with a 5-alpha-reductase inhibitor (finasteride): A methodologic approach
13. Progressive increase of apoptosis in prostatic intraepithelial neoplasia and carcinoma: Comparison between in situ end-labeling of fragmented DNA and detection by routine hematoxylin-eosin staining
14. Allelic loss in locally metastatic, multisampled prostate cancer
15. Strategy for repeat biopsy of patients with prostatic intraepithelial neoplasia detected by prostate needle biopsy
16. Prevalence and predictors of a positive repeat transrectal ultrasound guided needle biopsy of the prostate
17. Intraductal dysplasia: A premalignant lesion of the prostate
18. Cytological atypia in the prostate gland: Frequency, distribution and possible relevance to carcinoma
19. Age and racial distribution of prostatic intraepithelial neoplasia
20. Epidemiology of high grade prostatic intraepithelial neoplasia
21. Age and race distribution of high grade prostatic intraepithelial neoplasia: An autopsy study in Brazil (South America)
22. Analysis of repeated biopsy results within 1 year after a noncancer diagnosis
23. Incidence of high-grade prostatic intraepithelial neoplasia in sextant needle biopsy specimens
24. The association of selected pathological features with prostate cancer in a single-needle biopsy accession
25. Incidence and clinical significance of high-grade prostatic intraepithelial neoplasia in TURP specimens
26. Clinical significance of high-grade prostatic intraepithelial neoplasia in transurethral resection specimens
27. RER(+) phenotype in prostate intraepithelial neoplasia associated with human prostate carcinoma development
28. Genetic and chromosomal alterations in prostatic intraepithelial neoplasia and carcinoma detected by fluoresence in situ hybridization
29. Genetic heterogeneity in a prostatic carcinoma and associated intraepithelial neoplasia as demonstrated by combined use of laser-microdissection, degenerate oligonucleotide primed PCR and comparative genomic hybridization
30. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization
31. Nuclear chromatin texture in prostatic lesions. I. PIN and adenocarcinoma
32. Nuclear chromatin texture in prostatic lesions. II. PIN and malignancy associated changes
33. Expression of the RNA component of human telomerase (hTR) in prostate cancer, prostatic intraepithelial neoplasia, and normal prostate tissue
34. Telomerase activity, telomere length, and DNA ploidy in prostatic intraepithelial neoplasia (PIN)
35. Telomerase activity in prostate cancer, prostatic intraepithelial neoplasia and benign prostatic epithelium
36. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers
37. Detection of the apoptosis suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers
38. Bcl-2 immunoreactivity in prostate tumorigenesis in relation to prostatic intraepithelial neoplasia, grade, hormonal status, metastatic growth, and survival
39. Bcl-2 proto-oncogene expression in low- and high-grade prostatic intraepithelial neoplasia
40. Relation between bcl-2, cell proliferation, and the androgen receptor status in prostate tissue and precursors of prostate cancer
41. Comparative analysis of the nuclear proliferative index (Ki-67) in benign prostate, prostatic intraepithelial neoplasia, and prostatic carcinoma
42. Prostate stem cell compartments: Expression of the cell cycle inhibitor p27Kip1 in normal, hyperplastic, and neoplastic cells
43. Levels of expression of p27KIP1 protein in human prostate and prostate cancer: An immunohistochemical analysis
44. Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized prostate adenocarcinoma
45. Accumulation of the p53 protein occurs more frequently in metastatic than in localized prostatic adenocarcinomas
46. Immunohistochemical expression of retinoblastoma and p53 tumor suppressor genes in prostatic intraepithelial neoplasia: Comparison withprostate adenocarcinoma and benign prostate
47. Transformin growth factor-beta expression in prostate neoplasia
48. aFGF immunoreactivity in prostate cancer and its co-localization with bFGFand FGF8
49. Immunohistochemical analysis of midkine expression in human prostate carcinoma
50. Progression-linked overexpression of c-Met in prostatic neoplasia and latent as well as clinical prostate cancers
51. Human prostate cancer expresses the low affinity insulin-like growth factor binding protein IGFBP-rP1
52. Decreased immunoexpression of prostate inhibin peptide in prostatic carcinoma: A study with monoclonal antibody